NDAOPHTHALMICSOLUTION/DROPS
Approved
Jun 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHIBROXIN (norfloxacin) is a fluoroquinolone antibiotic administered as an ophthalmic solution for bacterial eye infections. It works by inhibiting bacterial DNA gyrase, preventing DNA replication in susceptible organisms. The product targets patients with conjunctivitis, corneal ulcers, and other ocular bacterial infections.
LOE Approaching
As a mature ophthalmic product approaching loss of exclusivity with moderate competitive pressure (30/100), commercial teams are likely focused on managed care and lifecycle extension strategies rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CHIBROXIN offers limited traditional career growth opportunities given its LOE trajectory and minimal linked job openings (0). Working on this product typically involves managing decline, negotiating payer contracts, and maximizing the tail revenue during generic transition rather than building the product from launch.
Brand ManagerField Sales Representative
Worked on CHIBROXIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.